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Abstract
Periodontal diseases are a major public health concern leading to tooth loss and also shown to be 
associated with several chronic systemic diseases. Smoking is a major risk factor for developing 
numerous systemic diseases, as well as periodontitis. While it is clear that smokers have a 
significantly enhanced risk for developing periodontitis leading to tooth loss, the population varies 
with regards to susceptibility to disease associated with smoking. This investigation focuses on 
identifying differences in four broad sets of variables consisting of: (a) host response molecules, 
(b) periodontal clinical parameters, (c) antibody measures for periodontal pathogens and oral 
commensal bacteria challenge, and (d) other variables of interest in a smoking population with (n 
= 171) and without periodontitis (n = 117). Subsequently, Bayesian network structured learning 
techniques (BNSL) techniques were used to investigate potential associations and cross-talk 
between the four broad sets of variables. BNSL revealed two broad communities with markedly 
different topology between the non-periodontitis and periodontitis smoking population. 
Confidence of the edges in the resulting network also showed marked variations within and 
between the periodontitis and non-periodontitis groups. The results presented validated known 
associations, as well as discovered new ones with minimal precedence that may warrant further 
investigation and novel hypothesis generation. Cross-talk between the clinical variables and 
antibody profiles of bacteria were especially pronounced in the case of periodontitis and mediated 
by the antibody response profile to P. gingivalis.
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INTRODUCTION
Periodontal diseases are a major public health concern leading to tooth loss and associated 
chronic systemic diseases (1–7). Bacterial-induced periodontal diseases have been 
categorized into two general types related to connective tissue attachment loss and alveolar 
bone resorption, ie. gingivitis and periodontitis. Gingivitis is a reversible inflammation of the 
gum tissue (i.e., gingiva) caused by the presence of a biofilm that forms on the tooth surface 
and resolves rather quickly after the reinstitution of mechanical and chemical oral hygiene 
procedures. Most individuals will experience at least mild and transient gingivitis at some 
time in their life (8–10). Periodontitis characterized by persistent gingival inflammation, 
breakdown of the connective tissue (i.e., attachment apparatus surrounding teeth), and 
destruction of alveolar bone (11, 12) with epidemiologic data supporting the concept of 
differential susceptibility to periodontitis regarding onset, rate of progression, and severity 
across the population (13, 14).
Smoking is a major risk factor for developing numerous systemic diseases, as well as 
periodontitis (15–18). Smokers frequently present with lower levels of gingival bleeding 
than would be predicted based upon the level of tissue destruction of the periodontium (19) 
This is likely due to effects of the smoke derived xenobiotics on local vascular functions (19, 
20), while tobacco smoke appears to amplify the inflammatory response to the microbial 
challenge (21–23). A report using NHANES III data determined that a population 
attributable risk (PAR) for current or former smoking was approximately 50% for exhibiting 
periodontitis (24). However, while it is clear that smokers have a significantly enhanced risk 
for developing periodontitis leading to tooth loss, the population varies with regards to 
susceptibility to disease associated with smoking (25, 26).
The oral ecology in an individual evolves over time with variations in quantity and quality of 
phyla, genera and species (27), as well as the genomic profile of the individual species (28–
30). However, this evolution generally leads to an equilibrium between the microbiota and 
the individual’s oral environment, as a climax community. The resulting microbial 
communities or biofilms are complex ecosystems of bacteria that are somewhat unique to 
various ecological niches in the oral cavity (31). The microbiomes of the subgingival 
environment of periodontally healthy and periodontally diseased sites are quite distinct (27, 
32). The accretion of tooth-associated bacterial biofilms elicits gingival inflammation as a 
result of bacterial virulence and metabolic factors affecting tissue vasculature. In sites 
colonized by more pathogenic biofilms, the inflammatory response results in destruction of 
connective tissue and alveolar bone, the classic features of periodontitis. Various extrinsic 
environmental factors can also affect the microbial composition in the oral cavity, as well as 
host response patterns. Recent studies have demonstrated clear effects of smoking on the 
composition of the microbiome at sites of periodontitis and peri-implantitis (33–36).
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The accumulation of these biofilms also elicits a robust inflammatory response with the 
cellular infiltrate releasing a panoply of pro-inflammatory molecules that initiate clinical 
inflammatory measures of gingival redness and edema (14, 37, 38). Numerous studies of 
gingival crevicular fluid at inflamed sites have identified associated biomolecules, such as 
IL-1β, PGE2, IL-10, and acute phase response proteins, including plasminogen activator 
inhibitor-1 (PAI-1) and myeloperoxidase (MPO), which can contribute to local antibacterial 
responses (39). The current paradigm in periodontal disease is a local chronic infection with 
microbial dysbiosis (40) that triggers a persistent destructive inflammatory response, rather 
than direct toxic/noxious actions of the bacterial virulence factors (41). Beyond innate 
immune and inflammatory responses, substantial literature documents the production of 
specific local and systemic antibodies to oral bacteria (38). Bacterial species-specific 
antibody levels increase significantly with periodontitis and decrease following therapy (14, 
38). Additionally, various studies have demonstrated alterations in the characteristics of the 
induced antibody in the presence of smoking (42–44). However, there is rather limited data 
regarding these adaptive immune responses in smokers presenting with a range of 
periodontal health and periodontal diseases.
The present study investigates changes in magnitude of four broad sets of variables 
consisting of: (a) host response molecules, (b) periodontal clinical parameters, (c) antibody 
measures of periodontal pathogens and oral commensal bacteria and (d) other variables of 
interest related to smoking population with (n = 171) and without periodontitis (n = 117). 
Subsequently, it investigates the potential associations and cross-talk between these variables 
using Bayesian network structured learning techniques (BNSL). BNSL is a probabilistic 
approach and widely used (45–47) to model direct as well as conditional dependencies 
between a given set of variables. In contrast to traditional statistical modeling, BNSL does 
not impose a pre-defined relationship between the given set of variables. It rather aims to 
discover these relationships from the data generated across the variables and abstract them as 
directed acyclic graphs (DAGs). The resulting DAGs can validate established associations as 
well as discover novel undocumented associations providing a more informed basis for 
hypothesis generation in addition to hypothesis testing. More importantly, a break down in 
associations across disease states is accompanied by marked changes in the topology or 
wiring pattern (48–50) of the DAGs as shown in this study. DAGs also serve as useful 
system-level abstractions of the concerted working of the variables that may not be readily 
apparent by investigating the variables in isolation. While BNSL has the potential to reveal 
causal relationships there are definite limitations to this approach. The DAG representation 
of the relationships between the variables in BNSL implicitly assumes absence of feedback 
between them. Such an assumption need not necessarily be true in general. Also, the number 
of potential structures in BNSL increases markedly with the number of variables 
discouraging an exhaustive search for all potential structures especially when the number of 
variables is large. PDAGs returned by BNSL essentially represents multiple structures that 
are probabilistically equivalent (equivalence class) as opposed to a single structure and may 
result in graphs comprising of directed as well as undirected edges. Thus BNSL can learn 
the associations between the variables only up to the equivalence class irrespective of the 
choice of the sample size. While directed edges may indicate potential causal relationships, 
undirected edges provide no such insights. However, it is important to note that causal 
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associations can be determined ideally only through active interventions. Thus associations 
returned by BNSL need to be validated experimentally using appropriate interventions.
MATERIALS and METHODS
Patient Population and Clinical Parameters
The cohort included 30 periodontally healthy subjects (M:F – 7:23), 55 gingivitis patients 
(M:F – 14:41), and 184 periodontitis patients (M:F – 73:111) ages 21–65 years. The 
protocol for this study was approved by the University of Kentucky Institutional Review 
Board and all participants signed an appropriate consent form. A comprehensive oral and 
periodontal examination was completed to assess the periodontal health. Inclusion/exclusion 
criteria for participating in the study: must be smokers, able to complete a questionnaire and 
sign a consent form, have a minimum of 20 teeth, willing to have blood drawn, whole saliva 
collected, and have a full periodontal evaluation.
Three clinical parameters routinely used for periodontal evaluation: (a) mean probing pocket 
depth (PPD), (b) clinical attachment level (51), and (c) bleeding on probing (BOP) were 
obtained from all patients. Full-mouth mean pocket depth and attachment level measured in 
millimeters (mm), and bleeding on probing, measured by percentage of sites in the mouth 
that bleed were determined at 6 sites per tooth excluding third molars (52). The 
measurements were taken and recorded by a single examiner. Measures of BOP and PPD 
were used to categorize the patients recognizing that various patients fell into “gray” areas. 
These “gray” area patients were assigned to a category and simply contributed to the 
variation within the different groups. We used a mean PPD ≤2.5 mm for non-periodontitis 
(ie. Health and Gingivitis) and ≥2.5 mm for periodontitis. While all Gingivitis subjects were 
categorized accurately (>20% sites BOP; mean PPD ≤2.5 mm), a subset of healthy subjects 
(26) had mean PD ≥2.5 mm, but limited % BOP and no sites with >4 mm pocket depths. 
Two of the periodontitis subjects had mean PPD ≤2.5 mm, but these subjects also had high 
% BOP and numerous sites with >4 mm pocket depths.
Variables such as age (Age), pack years of smoking (Yrs), salivary cotinine (Cot) levels, and 
body mass index (BMI) that have been traditionally investigated in periodontitis and 
smoking population studies were also included in the analysis.
Serum Analyses
Serum from a venipuncture blood sample was originally obtained from a group of 301 
smokers (age 21–65, 82 black, 219 white; 106 males, 195 females). After preliminary 
investigation and eliminating missing values the subjects were distributed to non-
periodontitis (NP; n=117) and periodontitis (PD; n=171) groups. The serum samples were 
stored at −80°C until the assays were performed. An array of oral microorganisms were used 
in the assays, cultivated under standard conditions, and prepared for antigens as described 
previously (53). The bacteria included periodontal pathogens: Aggregatibacter 
actinomycetemcomitans (Aa) strain JP2, Porphyromonas gingivalis (Pg) ATCC 33277, 
Treponema denticola (Td) ATCC 35405, and a group of oral commensal bacteria that 
included Streptococcus sanguinis (Ss) ATCC 10556, Actinomyces naeslundii (An) ATCC 
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49340, Veillonella parvula (Vp) ATCC 10790, Capnocytophaga ochracea (Co) ATCC 33596. 
An ELISA was used to determine the level of IgG antibody to the bacteria (52). Purified 
human IgG was bound to the plate to produce a standard curve. Sample data was 
extrapolated from this curve, using a four parameter logistic curve fit (54).
Molecular markers of inflammatory responses in serum, including interleukin-1β (IL-1β), 
plasminogen activator inhibitor-1 (PAI-1), myeloperoxidase (MPO), and IL-10 were 
evaluated using Luminex beadlyte technology (EMD Millipore, Billerica, MA) or 
commercial high sensitivity PGE2 ELISA ELISA kits (Assay Design, Ann Arbor, MI) (42).
Salivary cotinine levels were measured in whole saliva using an ELISA (Salimetrics’ High 
Sensitivity Salivary Cotinine Quantitative enzyme immunoassay kit, Carlsbad, CA) as we 
have described previously (43).
Statistical Analyses
Parametric t-test was used to identify those variables whose magnitude changed significantly 
across non-periodontitis and periodontitis groups after controlling the false-discovery rate 
(55). Variables whose adjusted p-values were significant (p < 0.02) are reported. 
Subsequently, BNSL was used to model potential associations between 15 variables 
comprising critical proteins (IL-1β, PAI-1), clinical parameters (BOP, PD, CAL), antibody 
to periodontal pathogens (Aa, Pg, Td) and oral commensal bacteria (Co, An, Vp, Ss), and 
other variables (Age, Yrs, Cot) across periodontitis and non-periodontitis subjects in the 
smoking population. Several techniques, such as constraint-based and search-score 
approaches, have been traditionally proposed in the literature for BNSL (56–58). Recent 
studies have shown that hybrid techniques such as max-min hill climbing (MMHC) that use 
a combination of constraint-based and search-score frameworks in tandem to outperform 
either of these approaches (59). Constraint-based part of MMHC uses max-min parents-
children approach to determine the skeleton of the underlying network. Subsequently, a 
Bayesian-greedy hill-climbing approach is used to determine the orientation of the edges in 
the skeleton. Partially directed acyclic graph (PDAG) representations that incorporate 
equivalence classes of the DAGs were subsequently generated (56, 57) in order to account 
for DAGs are probabilistically indistinguishable. Confidence of the edges (60, 61) in the 
PDAGs was determined from 1000 independently by resampling with replacement and 
edges with confidence less than 30% were deemed noisy, hence eliminated from further 
consideration. The remaining edges along with their confidences are reported as weighted 
graphs. Open-source implementation of the MMHC approach as a part of the bnlearn R 
package (62, 63) was used in the present study. Graphical layouts were generated using 
Gephi (64).
RESULTS
Adjusted p-values (p < 0.02) from a parametric t-test after controlling the false-discovery 
rate (55) revealed eight variables to exhibit a marked difference between the periodontitis 
(PD) and non-periodontitis (NP) groups (Table 1). As expected, the three clinical parameters 
(BOP, PPD, CAL) were significantly elevated in the periodontitis group as opposed to the 
NP group. As the groups were defined by clinical parameters, it was expected that these 
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would be significantly different. Of the remaining variables, IL-1β, PAI-1, pack-years of 
smoking, and antibody to P. gingivalis and A. naeslundii were also significantly elevated in 
the periodontitis group. Since previous results had not evaluated variations in host responses 
across clinical presentation in smokers, alterations in targeted inflammatory mediators and 
antibody levels, particularly to P. gingivalis, were undefined previously, but not totally 
unexpected.
Subsequently, Max-Min hill climbing approach was used to generate the Bayesian networks 
representing the interplay between 15 clinical and host response variables across the NP and 
PD smoking population. Confidence of the edges in the network was generated across 1000 
independent bootstrap realizations. The five sets of variables are shown by distinct colors in 
Figs.1a–1b for clarity and the thickness of the edges is proportional to their confidence 
represented in these figures. Edges whose confidences were <30% were deemed noisy, 
hence not reported. The networks corresponding to NP and PD exhibit two broad 
communities revealing intricate associations and cross-talk between (clinical parameters, 
other variables, Community 1) and (antibacterial responses, Community 2). However, there 
were substantial differences in the wiring pattern between them. Confidence of the edges 
showed marked variations within and between the NP and PD groups. While the network 
corresponding to NP is disconnected (Fig. 1a) that of the periodontitis patients is weakly 
connected (i.e. it is possible to traverse between any two variables in the underlying 
undirected graph) (Fig. 1b).
More importantly, in the case of periodontitis, antibody to P. gingivalis seems to act as a 
mediator establishing an association between otherwise unrelated variables (eg. CAL and 
Aa) and in turn establishing potential associations between the parameters of Community 1 
and 2. Unlike the PD group, there were no apparent relationships between BOP and mean 
pocket depth (PPD) in the case of the NP group. Scatter plots of (%BOP vs. PPD) also 
validated these findings with the absence of a significant direct association in the NP group 
(r=−0.15) as opposed to the PD group (r=0.58, p<0.01) (Fig. 2a). Our analysis also revealed 
some of the associations to be preserved across the NP and periodontitis groups. This 
includes the correlation between antibody to the pathogen (Aa) and commensal bacterium 
(Co) being reflected by prominent edges in Figs. 1a–1b. Aa and Co also exhibited a 
significant direct association across NP (r=0.58, p<0.01) as well as the PD (r=0.49, p<0.01) 
group (Fig. 2a). Associations between (Co and Td) were significant across NP (r=0.67, 
p<0.01) and PD (r=0.61, p<0.01) groups. Associations between (Co and Pg) were also 
significant across NP (r=0.63, p<0.01) and PD (r=0.39, p<0.01) groups (Fig. 2b).
Examining the associations of systemic inflammatory mediators to the clinical parameters in 
the population of smokers also provided an interesting profile. While numerous 
inflammatory biomarkers have been identified in serum and related to the extent and severity 
of periodontitis (23, 38, 65), the findings of this study in smokers provide a somewhat 
different outcome. Confidence of the edges corresponding to (IL-1β, PAI-1) was markedly 
higher in the periodontitis group as opposed to the non-periodontitis group, reflected by the 
discrepancy in the thickness of the edges in Fig. 1a–1b. This was also reflected by the 
marked decrease in the magnitude of the Pearson correlation between (IL–1β, PAI-1) from 
the PD group (r=0.34, p<0.01) compared to the NP group (r=0.20, p=0.03). Also, IL-1β was 
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associated with the clinical parameter (mean CAL) in the case of NP (Fig. 1a), whereas it 
was connected to the host response variables through linkage with antibody to the pathogen 
(T. denticola) in the case of PD (Fig. 1b). Also, the markers (IL-1β, PAI-1) did not exhibit a 
direct association to clinical disease parameters or smoking measures in the PD group. 
These results suggest that smoking may disrupt control of local and systemic inflammatory 
responses that occur related to the health of the periodontium. Active smoking (i.e. salivary 
cotinine levels) exhibited a strong association with the clinical parameter (CAL, p<0.01) in 
the NP group (Fig. 1a), unlike that of the PD group. While obesity has been reported to be 
linked to expression of periodontitis in humans (66–70), our data from a population of 
individuals who were all smokers showed that BMI did not exhibit a significant association 
to any of the clinical parameters, inflammatory responses, or specific antibody in either PD 
or NP individuals, hence not included in Figs. 1a–1b. These observations may indicate that 
certain biologic effects of smoking could overwhelm any contribution that modifiers elicited 
by overweight/obesity might have in altering the presentation of this oral disease. MPO and 
PGE2 exhibited a significant association across NP (r=0.50, p<0.01) and the PD (r=0.37, 
p<0.01) groups solely based on the correlation coefficients and associated p-values. 
However, as can be seen with the scatter plots (Fig. 3) the relationship is highly noisy, 
suggesting that the correlations may primarily reflect outlier values of a few subjects in the 
groups and hence are not identified as important contributors to the community relationships 
identified in Fig. 1a–1b. Additional variables demonstrated minimal or no relationship to 
these community linkages and are also not presented in the figure.
DISCUSSION
Smoking is one of, if not the major cause, of preventable morbidity and mortality in the 
population with substantial negative effects on general and oral health (16–18, 71). Smoking 
has been clearly delineated as a major modifiable environmental risk factor in the extent/
severity of periodontal disease through cross-sectional and longitudinal epidemiologic 
investigations (72). These data indicate that there is a 300–600% increase in periodontitis in 
smokers compared with non-smokers (73), and there clearly is a deleterious impact of the 
wide array of xenobiotics derived from smoking on the response to periodontal therapy (16, 
74). Nevertheless, while a significantly enhanced proportion of smokers exhibit periodontitis 
compared to the non-smoking population, clinical evaluation of smoking and periodontitis 
demonstrate a proportion of the smoking population remain periodontally healthy or only 
develop gingivitis (75). Another facet of the broader literature was that a subset of smokers 
appeared periodontally healthy even with long term smoking (ie. pack years) and substantial 
continine levels. Thus, some features of either the microbial challenge or characteristics of 
the host response profile appear to afford these patients an enhanced capacity to retain tissue 
homeostasis in the oral cavity. Similar observations have been summarized in a recent report 
by Genco and Borgnakke (69).
We have previously demonstrated serum antibody levels to selected oral pathogens and 
commensal bacteria related to race/ethnicity, age, and periodontal disease extent in a 
population of smokers (43), as well as systemic inflammatory responses related to smoking 
level (42). This study extended these findings by examining both serum antibodies and 
inflammatory molecules related to smoking parameters, and periodontal condition to 
Nagarajan et al. Page 7
J Periodontal Res. Author manuscript; available in PMC 2018 June 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
identify the impact of active smoking on the relationships among these various parameters. 
Serum levels of IL-1β were significantly elevated in the periodontitis patients. IL-1β has 
been identified to be a crucial molecule in chronic inflammatory responses, both locally and 
systemically (76). (77) (78). This pro-inflammatory mediator and bone resorbing cytokine 
does appear to contribute to the expression of periodontitis and has been linked to serum 
levels of C-reactive protein and altered IL-6 production appearing to play a role in 
periodontitis in type 2 diabetes mellitus (79). Our findings in smokers with periodontitis 
with the highest cotinine levels demonstrating elevated serum IL-1β provides additional data 
regarding the importance of this pro-inflammatory mediator in periodontitis.
A number of pro-inflammatory mediators are derived via the arachidonic acid pathway, 
including PGE2 (80), which has been implicated in the pathogenesis of gingival 
inflammation and periodontitis (81, 82). Additional biomarkers of inflammatory responses 
in the systemic circulation are components of the acute phase response, eg. PAI-1 (39). This 
array of molecules serves a range of functions with the goal of reestablishing systemic 
homeostasis following noxious challenge and have been related to periodontitis, periodontal 
therapy, and other chronic inflammatory diseases (83, 84) (85, 86) (87, 88) (83, 84). (89) 
(90), (91). Also, during the chronic inflammatory response reactive oxygen species (ROS) 
and free radicals (e.g., NO and NO2) are generated by neutrophils and macrophages, often 
through the action of myeloperoxidase (MPO) that is released into extracellular fluid at sites 
of inflammatory lesions (92, 93) and is affected by smoking (94) (95). Alterations in MPO 
have been identified to vary in periodontitis patients with/without treatment (86, 96, 97) (98) 
(86, 99).
Serum IgG antibody levels to a group of putative periodontal pathogens and oral commensal 
bacteria were also evaluated. As would be expected antibody to the periodontal pathogens 
were significantly elevated in the periodontitis smokers and significantly decreased in the 
periodontally healthy smokers. Substantial literature has demonstrated local and systemic 
adaptive immune responses to oral bacteria related to the presence, extent/severity, and 
therapeutic outcomes of periodontitis (38) (44) (51). We have found similar types of 
response differences in smokers related to the oral health of the individual; however, we 
extended the available literature by demonstrating a racial/ethnic contribution to these 
responses, as well as a difference in response profile to pathogenic compared to commensal 
oral bacteria (43). As importantly, the level of serum antibody to the oral bacteria has been 
shown to provide some reflection of the presence and burden of the particular 
microorganism within the oral cavity (100, 101). Thus, this measure is somewhat of a 
surrogate for the oral colonization, and could be suggested to reflect a challenge that the host 
sees as potentially deleterious and needs to be managed (100, 101). In this regard, the 
identification of antibody to A. actinomycetemcomitans interfacing with responses to P. 
gingivalis and T. denticola in the non-periodontitis smokers and also linked with clinical 
parameters in the periodontitis subset. Historically, periodontitis have been categorized as 
chronic adult and aggressive (102) and linked to microbiological characteristics with P. 
gingivalis and A. actinomycetemcomitans generally considered as representative of the 
major pathogens in these diseases (103) (38, 104). The majority of these studies intermixed 
both smokers and nonsmokers into their cohorts, and did often identify various clinical and 
biological differences related to smoking. However, our population comprised entirely of 
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smokers presented a somewhat unique profile. In the non-periodontitis (NP) group antibody 
levels to P. gingivalis and A. actinomycetemcomitans were associated with antibody to an 
important commensal species, C. ochracea, albeit, the level of antibody to these bacteria 
were significantly lower than in the periodontitis group, as was expected (38, 43). 
Interestingly, in the periodontitis patients antibody to C. ochracea, generally reflecting 
microbial challenge was associated with the group of commensal bacteria and provided a 
strong link to responses to the oral pathogens, ie. Aa, Pg, Td. This host response identifying 
these members of the microbial ecology was also uniquely related to the clinical and 
smoking community variables via responses to P. gingivalis. Thus, in the periodontitis 
patients, where P. gingivalis represents a hallmark bacteria and has been proposed as a 
keystone pathogen, the relationships in this smoking population reflected the capacity of P. 
gingivalis to interface clinical disease with a range of host responses.
These differences in responses were also obvious in demonstrating significant correlations of 
serum PGE2, IL-1β, and PAI-1 with various smoking parameters. In contrast, the serum 
antibodies lacked this type of relationship. We subsequently examined the direct relationship 
between the individual serum inflammatory mediators and the adaptive immune responses in 
subsets of patients stratified by salivary cotinine levels. The results demonstrated that in the 
subsets with lower cotinine levels, antibodies to a number of the commensal bacteria were 
significantly negatively correlated with serum PGE2 and MPO levels. In contrast, in the high 
cotinine group, antibody levels to the pathogens, and particularly P. gingivalis were 
significantly positively correlated with some of the inflammatory mediators (42). Thus, 
while antibodies were not directly correlated with cotinine and smoking levels, there 
appeared to be some interface between the systemic inflammatory and adaptive responses 
related to the interactions of smoking and periodontal disease.
The present study investigated variations in the magnitude of expression of four broad 
categories of variables between periodontitis and non-periodontitis smoking population. 
Subsequently, potential cross-talk and associations between these variables were investigated 
using a BNSL. In contrast to traditional statistical modeling BNSL does not impose any 
constraint on the associations between the variables rather discovers direct as well as indirect 
associations from the given data. This aspect of BNSL is especially useful in hypothesis 
generation. BNSL accommodates all the variables simultaneously and has the ability to 
provide system-level insights and potential cross-talk between them, thus, BNSL is 
markedly different from traditional reductionist approaches that investigate only subsets of 
variables in isolation. More importantly, BNSL has the ability to validate established 
associations, such as P. gingivalis responses in periodontitis and the relationship of age and 
amount of smoking to clinical measure of periodontal disease. Additionally, this approach 
can help to ascertain novel associations with minimal precedence, such as the relationship of 
select inflammatory mediators with clinical presentation on non-periodontitis smokers, 
inflammatory mediators linked more strongly to the microbial challenge in periodontitis, the 
centrality of the response to C. ochracea with response profiles to both commensals and 
pathogens, and the apparent ability of P. gingivalis to provide a bridge in linking bacterial 
responses to clinical parameters of disease in the periodontitis subset of smokers. More 
importantly, the results revealed marked variation in associations, their confidence as well as 
the overall network topology between the periodontitis and non-periodontitis groups. 
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Whether there are molecules in the xenobiotic mix of smoking products that trigger unique 
host response profiles, or this relationship reflects a general noxious challenge to host tissues 
and cells that results in some specificity for eliciting the inflammatory and adaptive 
responses remains to be determined. Thus, while periodontitis is considered to reflect a 
dysregulated host response to subgingival biofilms, these data suggest that smoking has the 
capacity to disrupt these responses to an even greater degree, thus increasing the risk for 
disease initiation/progression.
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Figure 1. 
Bayesian network representing potential associations between four broad sets of variables 
consisting of: (i) host response molecules (IL1β, PAI-1), (ii) periodontal clinical parameters 
(PD, BOP, CAL), (iii) antibody measures of periodontal pathogens (Aa, Pg, Td) and oral 
commensal bacteria (Co, Vp, An, Ss) and other variables (Age, Yrs, Cot) of interest in the 
non-periodontitis and the periodontitis smoking population is shown in (a) and (b) 
respectively. The four broad sets of variables are shown by different colors for clarity with 
the dotted lines representing the two broad communities in (a) and (b). The thickness of the 
edges in (a) and (b) are directly proportional to the edge confidence estimated from (N = 
1000) bootstrap realizations.
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Figure 2. 
(a) Scatter plot representing direct association between clinical parameters (Mean BOP) and 
(Mean PPD) was significant in the periodontitis (red, p<0.01) as opposed to the non-
periodontitis (blue) smoking population. Association between antibody to a periodontal 
pathogen (Aa) and a commensal bacteria (Co) was significant in periodontitis (red, p<0.01), 
as well as the non-periodontitis (blue, p<0.01) smoking population. (b) Scatter plot 
representing direct association between antibody to a periodontal pathogens (Td and Pg) and 
a commensal bacteria (Co) was significant in periodontitis (red, p<0.01), as well as the non-
periodontitis (blue, p<0.01) smoking population.
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Figure 3. 
Scatter plot representing potential association between serum levels of MPO and PGE2 for 
the non-periodontitis and periodontitis smoking population. The correlation is rendered 
significant (p < 0.01) by a few outliers in each of the case.
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Table 1
Average values and standard deviations of the 18 variables across between periodontitis and non-periodontitis 
smoking subjects.
Variable Non-Periodontitis Periodontitis
Clinical/Demographic
Age (years) 36.9±11.1 39.9±9.5
BMI 27.3±5.9 28.7±7.2
BOP** (% >0) 4.7±4.8 25.8±22
PPD** (mouth mean mm) 2.4±0.30 3.4±0.69
CAL** (mouth mean mm) 2.6±0.51 3.8±1
Smoking
Pack/years** 17.2±10 20.7±9.5
Salivary cotinine (ng/mL) 529.2±456.5 649.6±616.4
Inflammatory Mediators
IL-1β** (pg/mL) 39.1±56.7 79.6±99.8
PAI-1** (ng/mL) 110.7±139.3 160.4±157.5
MPO (ng/mL) 13056.5±7316.8 15238±9316.8
PGE2 (ng/mL) 531.5±818.6 472.9±709.8
Serum Antibody (ng/mL)
A. actinomycetemcomitans 15.3±12.9 18±13.6
A. naeslundii** 15.8±9.8 19.1±10.2
C. ochracia 10.2±5.6 11.7±7.3
P. gingivalis** 29±22 42.1±32
S. sanguinis 39.5±19.3 38.1±16.2
T. denticola 14.4±10.6 17.2±12.4
V. parvula 21.8±14.7 22±12.4
**
adjusted p-value < 0.02
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